KRW 4160.0
(-1.42%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 25.68 Billion KRW | 157.46% |
2022 | -44.7 Billion KRW | 74.64% |
2021 | -176.26 Billion KRW | -12476.26% |
2020 | 1.42 Billion KRW | 126.37% |
2019 | -5.4 Billion KRW | -330.63% |
2018 | 2.34 Billion KRW | 2105.41% |
2017 | 106.18 Million KRW | 993.92% |
2016 | -11.87 Million KRW | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 296.22 Million KRW | -88.73% |
2024 Q1 | 2.62 Billion KRW | -74.35% |
2023 FY | 25.68 Billion KRW | 157.46% |
2023 Q3 | 8.13 Billion KRW | 0.31% |
2023 Q4 | 10.25 Billion KRW | 25.99% |
2023 Q1 | -812.46 Million KRW | 93.9% |
2023 Q2 | 8.11 Billion KRW | 1098.38% |
2022 Q2 | -13.99 Billion KRW | 6.39% |
2022 FY | -44.7 Billion KRW | 74.64% |
2022 Q4 | -13.31 Billion KRW | -446.56% |
2022 Q3 | -2.43 Billion KRW | 82.59% |
2022 Q1 | -14.95 Billion KRW | -202.35% |
2021 FY | -176.26 Billion KRW | -12476.26% |
2021 Q3 | -184.82 Billion KRW | 0.0% |
2021 Q4 | 14.6 Billion KRW | 107.9% |
2020 FY | 1.42 Billion KRW | 126.37% |
2019 FY | -5.4 Billion KRW | -330.63% |
2018 FY | 2.34 Billion KRW | 2105.41% |
2017 FY | 106.18 Million KRW | 993.92% |
2016 FY | -11.87 Million KRW | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | -19.42 Billion KRW | 232.215% |
CMG Pharmaceutical Co., Ltd. | 6.45 Billion KRW | -297.904% |
Celltrion Pharm, Inc. | 21.26 Billion KRW | -20.79% |
Huons Global Co., Ltd. | 38.38 Billion KRW | 33.081% |
DongKook Pharmaceutical Co., Ltd. | 47.17 Billion KRW | 45.552% |
Enzychem Lifesciences Corporation | -9.32 Billion KRW | 375.412% |
Humedix Co., Ltd. | 24.82 Billion KRW | -3.487% |
Boditech Med Inc. | 25.94 Billion KRW | 1.004% |
EuBiologics Co., Ltd. | -13.87 Billion KRW | 285.072% |
FutureChem Co.,Ltd | -6.7 Billion KRW | 482.863% |
Huons Co., Ltd. | 50.47 Billion KRW | 49.109% |
AptaBio Therapeutics Inc. | -12.06 Billion KRW | 312.957% |